Khurana V G, Smith L A, Weiler D A, Springett M J, Parisi J E, Meyer F B, Marsh W R, O'Brien T, Katusic Z S
Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.
J Cereb Blood Flow Metab. 2000 Sep;20(9):1360-71. doi: 10.1097/00004647-200009000-00011.
Gene therapy is being investigated as a putative treatment option for cardiovascular diseases, including cerebral vasospasm. Because there is presently no information regarding gene transfer to human cerebral arteries, the principal objective of this study was to characterize adenovirus-mediated expression and function of recombinant endothelial nitric oxide synthase (eNOS) gene in human pial arteries. Pial arteries (outer diameter 500 to 1,000 microm) were isolated from 30 patients undergoing temporal lobectomy for intractable seizures and were studied using histologic staining, histochemistry, electron microscopy, and isometric force recording. Gene transfer experiments were performed ex vivo using adenoviral vectors encoding genes for bovine eNOS (AdCMVeNOS) and Escherichia coli beta-galactosidase (AdCMVLacZ). In transduced arteries, studied 24 hours after exposure to vectors, expression of recombinant beta-galactosidase and eNOS was detected by histochemistry, localizing mainly to the adventitia (n = 4). Immunoelectron microscopy localized recombinant eNOS in adventitial fibroblasts. During contractions to U46619, bradykinin-induced relaxations were significantly augmented in AdCMVeNOS-transduced rings compared with control and AdCMVLacZ-transduced rings (P < 0.01; n = 6). The NOS inhibitor L-nitroarginine methylester (L-NAME) caused significantly greater contraction in AdCMVeNOS-transduced rings (P < 0.001; n = 4) and inhibited bradykinin-induced relaxations in control and transduced rings (P < 0.001; n = 6). The current findings suggest that in AdCMVeNOS-transduced human pial arteries, expression of recombinant eNOS occurs mainly in adventitial fibroblasts where it augments relaxations to NO-dependent agonists such as bradykinin. Findings from the current study might be beneficial in future clinical applications of gene therapy for the treatment or prevention of cerebral vasospasm.
基因治疗正在作为心血管疾病(包括脑血管痉挛)的一种假定治疗选择进行研究。由于目前尚无关于基因转移至人脑血管的信息,本研究的主要目的是表征腺病毒介导的重组内皮型一氧化氮合酶(eNOS)基因在人软脑膜动脉中的表达和功能。从30例因顽固性癫痫接受颞叶切除术的患者中分离出软脑膜动脉(外径500至1000微米),并使用组织学染色、组织化学、电子显微镜和等长力记录进行研究。使用编码牛eNOS基因(AdCMVeNOS)和大肠杆菌β-半乳糖苷酶(AdCMVLacZ)的腺病毒载体进行离体基因转移实验。在暴露于载体24小时后研究的转导动脉中,通过组织化学检测到重组β-半乳糖苷酶和eNOS的表达,主要定位于外膜(n = 4)。免疫电子显微镜将重组eNOS定位于外膜成纤维细胞。在对U46619的收缩过程中,与对照和AdCMVLacZ转导环相比,AdCMVeNOS转导环中缓激肽诱导的舒张显著增强(P < 0.01;n = 6)。NOS抑制剂L-硝基精氨酸甲酯(L-NAME)在AdCMVeNOS转导环中引起显著更大的收缩(P < 0.001;n = 4),并抑制对照和转导环中缓激肽诱导的舒张(P < 0.001;n = 6)。目前的研究结果表明,在AdCMVeNOS转导的人软脑膜动脉中,重组eNOS的表达主要发生在外膜成纤维细胞中,在那里它增强了对缓激肽等NO依赖性激动剂的舒张作用。本研究的结果可能对基因治疗在治疗或预防脑血管痉挛的未来临床应用中有益。